PerspectivePublished 1 Oct 2022
New pharmaceutical approaches to address the cognitive impairment associated with chronic obstructive pulmonary disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
With over 3.23 million fatalities per year, chronic obstructive pulmonary disease (COPD) is currently the third leading cause of mortality in the world and a significant global health burden. Globally, COPD costs about €82 billion annually and significantly increases morbidity and mortality. Importantly, managing COPD's comorbidities and acute exacerbations brought on by viruses and bacteria accounts for a large portion of the disease burden and health care use in this condition (AECOPD). Recent clinical investigations have demonstrated that cognitive dysfunction, including deficits in executive function, memory, and attention, is present in up to 60% of persons with COPD. This has an impact on crucial outcomes like quality of life, hospitalization, and survival.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacology and Medicinal Chemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Marcellino Monda”
- BylineArticles whose byline prints “Rebecca Ross”
